The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Venlafaxine ER for the Treatment of Pediatric Subjects With Depression
Abstract
Objective The safety, efficacy, and tolerability of venlafaxine extended release (ER) in subjects ages 7 to 17 years with major depressive disorder were evaluated in two multicenter, randomized, double-blind, placebo-controlled trials conducted between October 1997 and August 2001.Method Participants received venlafaxine ER (flexible dose, based on body weight; intent to treat, n = 169) or placebo (intent to treat, n = 165) for up to 8 weeks. The primary efficacy variable was the change from baseline in the Children's Depression Rating Scale-Revised score at week 8.Results There were no statistically significant differences between venlafaxine ER and placebo on the Children's Depression Rating Scale-Revised in either study. A post hoc age subgroup analysis of the pooled data showed greater improvement on the Children's Depression Rating Scale-Revised with venlafaxine ER than with placebo (-24.4 versus -19.9; p = .022) among adolescents (ages 12-17), but not among children (ages 7-11). The most common adverse events were anorexia and abdominal pain. Hostility and suicide-related events were more common in venlafaxine ER-treated participants than in placebo-treated participants. There were no completed suicides.Conclusions Venlafaxine ER may be effective in depressed adolescents. However, its safety and efficacy in pediatric patients has not been established. Prescribers should monitor for signs of suicidal ideation and hostility in pediatric patients taking venlafaxine ER.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Three adolescent and young adult RCT studies found antidepressants reduced suicidal ideation,(62, 64, 65) one did not,(85) and none found a reduction in suicide behavior.”
From Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review (2021) · cites this paper as [85]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“Secondary outcome measures were the 21-Item Hamilton Rating Scale for Depression (HAM-D)21 (Hamilton, 1960), MontgomeryÅsberg Depression Rating Scale (MADRS; Montgomery and Åsberg, 1979), and CGI-S and CGI-Improvement scales.”
MethodA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
KAUFMAN, J., BIRMAHER, B., BRENT, D., RAO, U., FLYNN, C., MORECI, P., WILLIAMSON, D., & RYAN, N. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199707000-00021 · Cited by 10,148
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
(1976) · Medical Entomology and Zoology · Cited by 8,899
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
Emslie, G. J. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830230069010 · Cited by 985
Self-citationKELLER, M. B., RYAN, N. D., STROBER, M., KLEIN, R. G., KUTCHER, S. P., BIRMAHER, B., HAGINO, O. R., KOPLEWICZ, H., CARLSON, G. A., CLARKE, G. N., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200107000-00010 · Cited by 641 · cited 3×
“, 1997b, 1998, 2002), paroxetine (Braconnier et al., 2003; Keller et al., 2001), sertraline (Wagner et al.”
ResultInfluentialSelf-citationEMSLIE, G. J., HEILIGENSTEIN, J. H., WAGNER, K. D., HOOG, S. L., ERNEST, D. E., BROWN, E., NILSSON, M., & JACOBSON, J. G. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200210000-00010 · Cited by 581
Self-citationUnipolar Depression in Adolescents: Clinical Outcome in Adulthood
RAO, U., RYAN, N. D., BIRMAHER, B., DAHL, R. E., WILLIAMSON, D. E., KAUFMAN, J., RAO, R., & NELSON, B. (1995) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199505000-00009 · Cited by 514
Research works printed but not linked: 3
- DeVane, 1996, Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience, J Clin Psychiatry, 57, 55
- Kessler, 1998, Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the National Comorbidity Survey, Depress Anxiety, 7, 3, 10.1002/(SICI)1520-6394(1998)7:1<3::AID-DA2>3.0.CO;2-F · DOI · Paper page
- Sood, 2004, SSRIs in children and adolescents: where do we stand?, Curr Psychiatry, 3, 83
Cited by
Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., Ren, L., & Brent, D. A. (2007) · JAMA · doi:10.1001/jama.297.15.1683 · Cited by 1,086
Birmaher, B., & Brent, D. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318145ae1c · Cited by 1,056
“Secondary analysis of the venlafaxine trials showed an age effect, with these medications being better than placebo for depressed adolescents, but not depressed children (Emslie et al., 2007 [rct]); however, children were treated with low venlafaxine doses.”
BackgroundCipriani, A., Zhou, X., Del Giovane, C., Hetrick, S. E., Qin, B., Whittington, C., Coghill, D., Zhang, Y., Hazell, P., Leucht, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30385-3 · Cited by 734
Brent, D., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Keller, M., Vitiello, B., Ritz, L., Iyengar, S., Abebe, K., et al. (2008) · JAMA · doi:10.1001/jama.299.8.901 · Cited by 700
“Income, median (range), thousands $ 60 (8-500) 62 (0-250) .”
Self-citationImproving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review
Mann, J. J., Michel, C. A., & Auerbach, R. P. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20060864 · Cited by 655
Metadata
- Authors
- EMSLIE, G. J., FINDLING, R. L., YEUNG, P. P., KUNZ, N. R., & LI, Y.
- Affiliations
- Yale University (US)
- Corresponding author
- EMSLIE, GRAHAM J.
- Venue
- Journal of the American Academy of Child & Adolescent Psychiatry
- Publisher
- Elsevier BV
- Published
- 2007-04
- Volume
- 46
- Issue
- 4
- Pages
- 479-488
- ISSN
- 0890-8567 (ISSN-L)
- OpenAlex
- W1520036360
- Cited by
- 135
- References
- 29
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 10 · 2023: 5 · 2022: 7 · 2021: 6 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 9 · 2016: 9 · 2015: 5 · 2014: 8 · 2013: 8 · 2012: 11
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- venlafaxine extended release, childhood depression, major depressive disorder, adolescents, Children's Depression Rating Scale-Revised, antidepressant efficacy, adverse events, anorexia, hostility, suicidal ideation, suicide risk, drug safety
- MeSH terms
- Venlafaxine Hydrochloride, Adolescent, Algorithms, Child, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Depressive Disorder, Major, Double-Blind Method, Female, Humans, Male, Placebos, Suicide, Attempted, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Venlafaxine ER for the Treatment of Pediatric Subjects With Depression. https://app.cochat.ai/papers/10.1097/chi.0b013e31802f5f03
- The paper
- EMSLIE, G. J., FINDLING, R. L., YEUNG, P. P., KUNZ, N. R., & LI, Y. (2007). Venlafaxine ER for the Treatment of Pediatric Subjects With Depression. Journal of the American Academy of Child & Adolescent Psychiatry. https://doi.org/10.1097/chi.0b013e31802f5f03
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.